Related Experiment Video
Updated: Feb 1, 2026

Author Spotlight: Establishment and Confirmation of a Postnatal Right Ventricular Volume Overload Mouse Model
Published on: June 9, 2023
Ibrutinib should be a standard of care for many patients with chronic lymphocytic leukemia, according to results from two phase III trials. The BTK inhibitor, given alone or in combination with rituximab, improved clinical outcomes-including progression-free survival-when compared with chemoimmunotherapy regimens.
Ibrutinib should be a standard of care for many patients with chronic lymphocytic leukemia, according to results from two phase III trials. The BTK inhibitor, given alone or in combination with rituximab, improved clinical outcomes-including progression-free survival-when compared with chemoimmunotherapy regimens.
Related Concept Videos
Confirmation Biases
Protein Folding
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Feedback Inhibition
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Monohybrid Crosses

